Ategenos Gears Up for Transformation in Medication Adherence
Ategenos is making headlines as it prepares for a significant public launch under the leadership of its co-founder and CEO, Don DeGolyer. The company focuses on solving a pressing issue in healthcare: medication non-adherence, which impacts healthcare costs and patient outcomes dramatically.
Addressing Global Healthcare Challenges
As a tech-driven pharma company, Ategenos aims to tackle the crisis of medication non-adherence, which is estimated to cost the healthcare system over $1 trillion globally every year. DeGolyer emphasizes this challenge, stating, "Medication doesn’t work if it’s not taken," underlining the importance of adhering to prescribed treatments.
Innovative Solutions with SmartPatch
Ategenos has been developing its innovative SmartPatch platform, which integrates pharmaceutical science with advanced digital health technologies. This platform is designed to enhance adherence in critical dose management, equipping caregivers with the tools necessary to ensure their loved ones receive their medication safely and reliably.
Caregiver Support and Real-Time Data
The SmartPatch will offer caregivers peace of mind by providing them access to real-time data on their loved ones' medication adherence. This approach not only helps prevent potential health crises but also fosters better relationships between patients and caregivers.
The Expertise of Don DeGolyer
With more than four decades in the pharmaceutical industry, DeGolyer's leadership experience is invaluable. He previously achieved a remarkable revenue increase of $2 billion during his time as President & CEO of Sandoz Inc., establishing a robust generics business in North America. His diverse background includes key achievements as COO of Endo Pharmaceuticals, where he immensely increased market capitalization.
Building a Dynamic Founding Team
DeGolyer has assembled a founding team that combines pharmaceutical expertise, technological innovation drawing from MIT, and knowledge of venture capital. This powerful fusion positions Ategenos uniquely within the healthcare landscape, allowing it to innovate effectively.
About Ategenos
Ategenos, based in Massachusetts, is dedicated to enhancing patient quality of life through its SmartPatch platform. This advanced transdermal system not only ensures sustained drug delivery but also features real-time monitoring and intervention capabilities for caregivers. The overarching goal is to minimize health risks, reduce hospital admissions, and ultimately address the significant costs stemming from missed medication doses.
Strategy for Success
The strategic vision of Ategenos is rooted in leveraging advanced technology alongside traditional pharmaceutical practices. This comprehensive approach aims to ensure that patients adhere to their medication schedules, benefiting both their health and the overall health system.
Frequently Asked Questions
What is Ategenos focused on addressing?
Ategenos focuses on tackling medication non-adherence, a challenge that leads to significant healthcare costs and patient risks.
What is the SmartPatch?
The SmartPatch is a platform developed by Ategenos to combine drug delivery with real-time monitoring to support patient adherence.
Who is Don DeGolyer?
Don DeGolyer is the co-founder and CEO of Ategenos and has extensive leadership experience in the pharmaceutical industry.
What are the goals of Ategenos?
The primary goals of Ategenos include improving patient adherence to medications and reducing the healthcare costs associated with non-adherence.
How does Ategenos support caregivers?
Ategenos equips caregivers with real-time data and tools to ensure their loved ones take medications as prescribed, helping prevent health crises.
